Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
Open Access
- 1 January 2018
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 28 (1), 152-160
- https://doi.org/10.1097/igc.0000000000001129
Abstract
ObjectivesAL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). This study evaluates the efficacy of AL3818 studying tumor regression in an orthotopic murine endometrial cancer model.MethodsWe tested the cytotoxicity of AL3818 on a panel of 7 human endometrial cancer cell lines expressing either wild-type or mutant FGFR2 and also assessed the in vivo antitumor efficacy in a murine, orthotopic AN3CA endometrial cancer model. AL3818 was administered daily per os either alone or in combination with carboplatin and paclitaxel, which represent the current standard of adjuvant care for endometrial cancer.ResultsAL3818 significantly reduces AN3CA cell number in vitro, characterized by high expression of a mutated FGFR2 protein. Daily oral administration of AL3818 (5 mg/kg) resulted in a complete response in 55% of animals treated and in a reduced tumor volume, as well as decreased tumor weights of AN3CA tumors by 94% and 96%, respectively, following a 29-day treatment cycle. Whereas carboplatin and paclitaxel failed to alter tumor growth, the combination with AL3818 did not seem to exhibit a superior effect when compared with AL3818 treatment alone.ConclusionsAL3818 shows superior efficacy for the treatment of endometrial cancer irresponsive to conventional carboplatin and paclitaxel combination and warrants further investigation.Keywords
This publication has 30 references indexed in Scilit:
- High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently MutatedPLOS ONE, 2012
- Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2012
- FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological FeaturesPLOS ONE, 2012
- Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New AgentsThe Oncologist, 2010
- Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined ModalitiesThe Oncologist, 2010
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences of the United States of America, 2008
- Carboplatin and paclitaxel in advanced or metastatic endometrial cancerGynecologic Oncology, 2008
- A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine KinasesMolecular Cell, 2007
- Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesOncogene, 2007
- Sulforhodamine B colorimetric assay for cytotoxicity screeningNature Protocols, 2006